Crossref
CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer
Int. Journal of Clinical Pharmacology and Therapeutics · 09.11.2026
DOI: 10.5414/cp205039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 09.11.2026. Verfasst von Dongdong Wang und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, D., & Zhou, G. (2026). CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp205039
Vancouver
Wang D, Zhou G. CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer. Int. Journal of Clinical Pharmacology and Therapeutics. 2026. doi:10.5414/cp205039
BibTeX
@article{Wang2026,
author = {Wang, Dongdong and Zhou, Guozhi},
title = {CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
doi = {10.5414/cp205039}
}
EUVIMED